Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - SALIX PHARMACEUTICALS LTD | d231216d10q.htm |
| EX-31.1 - SECTION 302 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTD | d231216dex311.htm |
| EX-32.1 - SECTION 906 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTD | d231216dex321.htm |
| EX-31.2 - SECTION 302 CFO CERTIFICATION - SALIX PHARMACEUTICALS LTD | d231216dex312.htm |
| EX-10.86 - AGREEMENT FOR ADVANCE AGAINST COMMITMENT FEE - SALIX PHARMACEUTICALS LTD | d231216dex1086.htm |
| EX-10.29.2 - THIRD AMENDMENT TO LEASE DATED OCTOBER 18, 2011 BETWEEN EOS ACQUISITION I LLC - SALIX PHARMACEUTICALS LTD | d231216dex10292.htm |
| EXCEL - IDEA: XBRL DOCUMENT - SALIX PHARMACEUTICALS LTD | Financial_Report.xls |
| EX-10.85 - AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT - SALIX PHARMACEUTICALS LTD | d231216dex1085.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended September 30, 2011 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Adam C. Derbyshire, Executive Vice President, Finance and Administration, and Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report. |
| Date: November 9, 2011 | By: | /s/ Adam C. Derbyshire | ||||
| Adam C. Derbyshire Executive Vice President and Chief Financial Officer |
44